Novartis buys S Africa-based Aspen’s Japanese generic unit for up to $440m

Novartis is buying the Japanese generics unit of South Africa’s Aspen Pharmacare in a deal worth up to 400 millioneuros ($440.80 million) to expand in the world’s third-biggest drug market, the Swiss drugmaker said on Monday.